奈妥匹坦帕洛诺司琼(Netupitant/Palonosetron Hydrochloride) - 药物靶点：HTR3 x NK1R_在研适应症：恶心，呕吐，化疗引起的恶心和呕吐_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Akynzeo、FOSNETUPITANT CHLORIDE HYDROCHLORIDE/PALONOSETRON HYDROCHLORIDE、Fosnetupitant/palonosetron

+ [9]

靶点

HTR3 x NK1R

作用方式

拮抗剂

作用机制

5-HT3 receptor拮抗剂(5-羟色胺受体3拮抗剂)、NK1R 拮抗剂(神经激肽-1-受体拮抗剂)

治疗领域

其他疾病肿瘤神经系统疾病+ [2]

在研适应症

恶心呕吐化疗引起的恶心和呕吐+ [3]

非在研适应症

乳腺癌

原研机构

Helsinn Healthcare SA

在研机构

Helsinn Healthcare SA

Helsinn Birex Pharmaceuticals Ltd.

Knight Therapeutics, Inc.

+ [4]

非在研机构

Helsinn Therapeutics (U.S.), Inc.

权益机构

Purdue Pharma LP

上海复星医药（集团）股份有限公司Chugai Pharma Europe Ltd.

+ [10]

最高研发阶段批准上市

首次获批日期

美国 (2014-10-10),

化疗引起的恶心和呕吐

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C19H25ClN2O

InChIKeyOLDRWYVIKMSFFB-SSPJITILSA-N

CAS号135729-62-3

查看全部结构式(2)

关联

43

项与奈妥匹坦帕洛诺司琼相关的临床试验

ChiCTR2600119239

/ Not yet recruitingN/AIIT

Exploratory Clinical Study on the Dexamethasone-Free, Optimized Antiemetic Regimen with NEPA (Netupitant-Palonosetron) Capsules for Preventing Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately to Highly Emetogenic Chemotherapy

开始日期2026-02-04

申办/合作机构

厦门大学附属中山医院（厦门中山医院、厦门市老年病康复研究所、厦门市消化疾病研究所、厦门市临床检验中心）

ChiCTR2600116296

/ Not yet recruiting临床4期IIT

To evaluate the efficacy and safety of NEPA combined with Megestrol Acetate versus NEPA combined with Dexamethasone in preventing nausea and vomiting caused by T-Dxd in breast cancer patients

开始日期2026-01-30

申办/合作机构-

NCT07254416

/ Not yet recruiting临床4期IIT

To Evaluate the Efficacy and Safety of NEPA Combined With Megestrol Acetate Versus NEPA Combined With Dexamethasone in Preventing Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients

This study was a multicenter, prospective, controlled trial involving 120 breast cancer patients receiving T-DXd-based therapy. Participants were randomly assigned to either the experimental group (NEPA plus megestrol acetate) or the control group (NEPA plus dexamethasone), with 60 patients in each group. The intervention was administered over two treatment cycles. During this period, the onset time, frequency, and severity of nausea and vomiting were recorded and subjected to statistical analysis.
The primary objective of this study was to evaluate the efficacy and safety of netupitant/palonosetron capsules (NEPA) combined with megestrol acetate compared to the standard triple antiemetic regimen (NEPA plus dexamethasone) in preventing chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients undergoing T-DXd-containing regimens. The findings aim to generate clinical evidence to support optimal antiemetic management, minimize the risk of dose reduction or treatment discontinuation due to gastrointestinal adverse events, and ultimately improve patient quality of life.

开始日期2025-12-15

申办/合作机构

天津市肿瘤医院（天津医科大学肿瘤医院）

[+1]

100 项与奈妥匹坦帕洛诺司琼相关的临床结果

登录后查看更多信息

100 项与奈妥匹坦帕洛诺司琼相关的转化医学

登录后查看更多信息

100 项与奈妥匹坦帕洛诺司琼相关的专利（医药）

登录后查看更多信息

125

项与奈妥匹坦帕洛诺司琼相关的文献（医药）

2026-02-01·ANNALS OF ONCOLOGY

Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial

Article

作者: Stimamiglio, V ; Tomlins, E ; Roeland, E J ; Cheng, Y ; Brozos Vázquez, E ; Syrigos, K ; Zhou, Z ; Dranitsaris, G ; Aapro, M ; Schwartzberg, L ; Mavroudis, D ; García Alfonso, P ; Christoph, D C ; Majem, M ; Molassiotis, A ; Zimovjanová, M ; Olivari Tilola, S ; Karthaus, M ; Alonzi, A ; Jordan, K ; Bonizzoni, E ; Lu, X ; Buchler, T

BACKGROUND:

Patients receiving moderately emetogenic chemotherapy (MEC) are commonly prescribed a 5-hydroxytryptamine-3 (5-HT₃) receptor antagonist (RA) and dexamethasone (DEX) as standard-of-care (SOC) antiemetic prophylaxis. However, in patients with an elevated risk of chemotherapy-induced nausea and vomiting (CINV) due to individual risk factors, prophylaxis with an neurokinin-1 (NK₁) RA-containing regimen may optimise their antiemetic prevention. To address this unmet need for a more personalised antiemetic strategy, the MyRisk trial incorporated a predictive risk factor algorithm to select patients at increased risk of CINV who may benefit from enhanced antiemetic prophylaxis.

PATIENTS AND METHODS:

MyRisk was a phase IV, randomised, open-label, multicentre, multinational trial. Adult patients scheduled to receive three cycles of MEC with a high-risk CINV score were randomly assigned to NEPA (a fixed combination of an NK₁ RA, netupitant, and 5-HT₃ RA, palonosetron) + DEX or SOC. The CINV risk score was calculated based on an algorithm that considered seven risk factors. The primary endpoint was complete response (CR: no emesis/no rescue medication) during the overall phase (0-120 h) across three consecutive cycles.

RESULTS:

Of 401 randomly allocated patients, 388 were included in the efficacy analysis. The most common cancers were colorectal and lung; oxaliplatin and carboplatin were the most common MECs. Patients randomly assigned to NEPA were significantly more likely to experience a CR compared with SOC (odds ratio 1.67, 95% confidence interval 1.12-2.49, P = 0.012). The NEPA group had a significantly higher probability of CR, no nausea, no emesis, and complete protection (81.0%, 63.7%, 95.4%, and 71.8%, respectively) compared with the SOC arm (71.8%, 54.9%, 86.7%, and 62.4%, respectively) across three cycles of chemotherapy.

CONCLUSIONS:

When individual risk factors are considered before MEC, a three-drug regimen including NEPA provides superior CINV prevention across multiple cycles compared with the standard two-drug approach. These findings underscore the value of personalised risk-adapted antiemetic strategies and have practice-changing potential for optimising antiemetic control.

2026-02-01·SUPPORTIVE CARE IN CANCER

Bioequivalence of netupitant and palonosetron (NEPA) oral suspension and hard capsules in healthy individuals: results from an open-label, randomized, two-treatment, four-period, two-sequence replicative design trial

Article

作者: Bezzo, Riccardo ; Seitz, Friedeborg ; Gasanin, Edis ; Spinelli, Tulla

PURPOSE:

NEPA, a fixed-antiemetic combination of netupitant and palonosetron, is available via two administration routes (oral and intravenous). A new oral suspension was developed to offer a more convenient option for patients. This study evaluated the bioequivalence between the oral capsule and the oral suspension.

METHODS:

Open-label, randomized, single-center phase I trial conducted according to a two-treatment, four-period, two-sequence replicative design. Two treatments were investigated for bioequivalence: a 10-mL oral suspension (Test [T]) and the hard capsule (Reference [R]), both containing 300 mg netupitant/0.5 mg palonosetron. Healthy individuals were randomized (1:1) to receive two doses of both Test and Reference formulations, in either T-R-T-R or R-T-R-T sequence. The primary objective was to demonstrate AUC_0-t bioequivalence of netupitant and palonosetron after a single dose of Test and Reference formulations.

RESULTS:

In total, 72 participants were included. The geometric mean plasma concentration-time profiles of netupitant and palonosetron were similar for the Test and Reference formulations. The AUC_0-t geometric means of both analytes were similar for the Test and Reference formulations. The 90% confidence interval of the Test/Reference ratios for AUC_0-t of netupitant and palonosetron were within the acceptance range for bioequivalence of 80-125%. The AUC_0-t variability was moderate for netupitant and low for palonosetron. Both formulations were well tolerated.

CONCLUSION:

The NEPA oral suspension is pharmacokinetically bioequivalent to the capsule formulation in healthy individuals, with no new safety concerns. These findings support NEPA oral suspension as a potentially beneficial option for patients who prefer an oral suspension over a hard capsule and for those with swallowing difficulties. EUCT Number: 2023-504355-28-00 (25/08/2023).

2025-12-01·Asia-Pacific Journal of Clinical Oncology

The Double‐Blind Placebo‐Controlled Study Comparing Upfront and Subsequent Netupitant in Addition to Olanzapine‐Containing Regimen for Prevention of High‐Dose Cisplatin‐Induced Nausea/Vomiting

Article

作者: Sitthideatphaiboon, Piyada ; Chotirut, Attapol ; Mahaparn, Wasamol ; Zungsontiporn, Nicha ; Tanasanvimon, Suebpong ; Lertanansit, Chalermchai ; Uttamapinan, Suleepon ; Vinayanuwattikun, Chanida ; Sintawichai, Nattaya ; Sriuranpong, Virote

ABSTRACT:

Background:

Addition of olanzapine to NK‐1 receptor antagonist regimen improves chemotherapy‐induced nausea and vomiting (CINV) prevention for highly emetogenic chemotherapies (HECs). However, the benefit of addition of NK‐1 receptor antagonist to olanzapine regimen has not been demonstrated. This study compared the efficacy of upfront and subsequent addition of netupitant‐ to olanzapine‐containing regimen for preventing CINV from high‐dose cisplatin (≥ 75 mg/m 2 ).

Patient and Methods:

The double‐blind placebo‐controlled trial randomized patients receiving high‐dose cisplatin to upfront and subsequent netupitant arms. In upfront netupitant arm, patients received NEPA (a combination of netupitant and palonosetron), dexamethasone, and olanzapine since first cycle. In subsequent netupitant arm, patients received olanzapine, dexamethasone, and ondansetron in first cycle but received NEPA, dexamethasone, and olanzapine in second cycle if no complete response (CR). After preplanned analysis, the initial dexamethasone dose in netupitant regimen was modified from 4 to 8 mg on Days 2–4. The primary endpoint was the overall CR rate of two cycles.

Results:

Between January 2019 and December 2020, 51 and 49 patients were randomly assigned to upfront and subsequent netupitant arms, respectively. CR rates in acute (0–24 h), delayed (> 24–120 h), and overall periods were 93.0% versus 77.4% ( p = 0.003), 75.5% versus 68.8% ( p = 0.31), and 73.3% and 67.7% ( p = 0.34) in upfront and subsequent netupitant arms, respectively. After amendment to increase dexamethasone in netupitant regimen, first‐cycle CR rates in acute, delayed, and overall periods were 95.2% versus 87.7% ( p = 0.34), 85.7% versus 73.5% ( p = 0.26), and 85.7% and 69.4% ( p = 0.26) in 4‐drug and 3‐drug groups, respectively. Among 15 patients crossing over to receive netupitant regimen in second cycle, CR was 46.6%.

Conclusion:

In this Phase II trial, there was no significant improvement in overall CR when patients received upfront netupitant compared to subsequent addition of netupitant to an olanzapine regimen in patients receiving high‐dose cisplatin chemotherapy.

89

项与奈妥匹坦帕洛诺司琼相关的新闻（医药）

2026-02-25

·米内网

【市场】17个国谈药拟进院，独家品种霸屏

精彩内容近日，成都市第六人民医院发布招标公示，将组织拟引入药品生产企业遴选工作。17个新药在列，均为国谈药，涵盖化学药及生物药，既有环泊酚注射液等超10亿大品种，亦有芦比前列酮软胶囊、替戈拉生片等2025年前三季度销售额增速达三位数的高增长品种。 17个新药均为国谈药，目前均已纳入国家医保乙类目录，主要集中在消化系统及代谢、神经系统、心脑血管系统等治疗领域，可见以慢病药、常见病药为主。此次拟进院的新药在剂型上较为丰富，包括普通片剂、胶囊剂、注射剂、滴眼剂等，其中以注射剂、普通片剂为主。独家品种（含独家剂型）占比超八成，包括恒瑞医药的富马酸泰吉利定注射液、海思科的环泊酚注射液及安瑞克芬注射液、南京正大天晴的芦比前列酮软胶囊等国产品牌，以及诺和诺德的依柯胰岛素注射液、礼来的替尔泊肽注射液、诺华的英克司兰钠注射液等进口品牌。拟引入药品目录（2026年第一批）注：标*为独家品种来源：成都市第六人民医院，米内网数据库海思科开发的环泊酚注射液最早于2020年12月获批上市，为国内获批的首个1.1类静脉麻醉药，目前已有3个适应症纳入国家医保乙类目录。米内网数据显示，该药近年来在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端迅速放量，2025年前三季度销售额接近13亿元，同比增长约64%。近年来中国公立医疗机构终端环泊酚注射液销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局芦比前列酮软胶囊（南京正大天晴独家）、替戈拉生片（罗欣药业独家）、奈妥匹坦帕洛诺司琼胶囊、英克司兰钠注射液（诺华独家）等品种2025年前三季度在中国公立医疗机构终端的销售额增速均达三位数。罗欣药业开发的替戈拉生片最早于2022年4月获批上市，为国内获批的首个新型钾离子竞争性酸阻滞剂(P-CAB)类药物，目前已有3个适应症纳入国家医保乙类目录。该药近年来在中国公立医疗机构终端的销售额均以三位数的增速持续增长，2025年前三季度超过6亿元，远超2024年全年水平。近年来中国公立医疗机构终端替戈拉生片销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局值得注意的是，此次申报进院药品的纸质申报资料报送时间为2026年2月28日（8:00-12:00），逾期不予接收，不接受邮寄送达。资料来源：米内网数据库、成都市第六人民医院等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至2月25日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

2026-02-09

·药事纵横

恒瑞医药创新止吐药拓展新适应症，为中度致吐化疗患者带来新选择

1月30日，恒瑞医药宣布其自主研发的注射用磷罗拉匹坦帕洛诺司琼新适应症上市许可申请获正式受理。该药拟定用于预防成年患者因中度致吐性抗肿瘤药物引起的急性和迟发性恶心呕吐。化疗恶心呕吐长期以来是肿瘤患者治疗过程中的常见不良反应。根据国内外权威指南，这些症状严重时可导致脱水、电解质紊乱、营养缺乏甚至食管黏膜撕裂等严重后果，显著影响患者生活质量和治疗依从性。在预防策略上，临床指南已有明确分层：对于高致吐性化疗方案，推荐使用包含NK-1受体拮抗剂和5-HT3受体拮抗剂的三联或四联方案。而对于中度致吐性化疗，传统上主要推荐5-HT3受体拮抗剂联合地塞米松的二联方案。对于那些使用中度致吐风险相对较高的抗肿瘤药物、合并高危因素，或先前接受二联预防仍出现恶心呕吐的患者，指南推荐升级为三联方案。预防性用药是控制恶心呕吐的关键，但受联合用药繁琐、对迟发性呕吐预期不足、患者居家漏服等因素影响，临床中的指南依从性并不理想。注射用磷罗拉匹坦帕洛诺司琼是一款复方制剂，能够同时拮抗NK-1受体和5-HT3受体，通过双途径抑制呕吐反射。从药物成分来看，该产品由磷罗拉匹坦和帕洛诺司琼组成，其中HRS5580作为罗拉匹坦前药，进入体内后能够迅速转化为活性成分罗拉匹坦。这一转化过程主要通过非CYP450酶系水解完成，避免了与多种药物的相互作用。帕洛诺司琼作为第二代5-HT3受体拮抗剂，能够有效阻断外周和中枢的5-HT3受体，对化疗急性期（化疗后24小时内）的恶心呕吐控制效果显著且持久。而罗拉匹坦作为长效NK-1受体拮抗剂，半衰期长且具有高度的中枢神经系统渗透性，在预防延迟期（化疗后24-120小时）和超延迟期的呕吐中展现出独特优势。此次新适应症的申请，基于一项代号为HR20013-302的多中心、随机、双盲、阳性对照的Ⅲ期临床试验。该研究由中山大学肿瘤防治中心牵头，张力教授和李宇红教授担任主要研究者，全国96家临床研究中心共同参与，共随机入组706例受试者。研究的主要终点和关键次要终点分别为中致吐性抗肿瘤药物给药开始后延迟期和总体期完全缓解的受试者比例。研究结果显示，试验组在延迟期完全缓解率和总体期完全缓解率方面均显著优于对照组。除主要疗效终点外，试验组在症状控制、生活质量改善、至治疗失败时间以及不同特征人群亚组分析等多个维度，均较对照组显示出一致优势。在安全性方面，试验组的安全性与耐受性良好，未发现新的安全性信号。这款药物已于2025年5月在国内首次获批上市，用于预防成人高致吐性化疗导致的急性和迟发性恶心呕吐。支持其首个适应症获批的关键Ⅲ期PROFIT研究（NCT05509634）主要结果已发表于国际著名肿瘤学期刊《临床肿瘤学杂志》。研究表明，磷罗拉匹坦帕洛诺司琼在每个治疗周期内仅需用药一次，便可同时覆盖高致吐性化疗给药后引起的急性期、延迟期及超延迟期恶心呕吐。在全球范围内，已上市的同类NK-1受体/5-HT3受体拮抗剂复方制剂主要为瑞士Helsinn Healthcare公司的AKYNZEO系列，包括静脉注射制剂（福奈妥匹坦/帕洛诺司琼）以及口服胶囊制剂（奈妥匹坦/帕洛诺司琼）。目前，国内已上市AKYNZEO口服胶囊制剂，但暂无同类注射剂获批上市。这意味着，如果恒瑞医药的注射用磷罗拉匹坦帕洛诺司琼新适应症获批，将成为国内首个该类药物注射剂型，填补市场空白。国内市场已有超过10家企业的阿瑞匹坦仿制药获批，30家企业的帕洛诺司琼仿制药上市。立即扫码加入药事纵横交流群

2026-02-09

·BioSpace

Helsinn and ESTEVE expand their partnership extending the Distribution and Licence Agreement for AKYNZEO® and ALOXI® to Austria

Helsinn and ESTEVE expand their partnership extending the Distribution and Licence Agreement for AKYNZEO ® and ALOXI ® to Austria Lugano, Switzerland – February 9th, 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, and ESTEVE, an international pharma company with a focus on highly specialized treatments that address significant unmet medical needs, today announced that they have expanded their relationship by extending the Distribution and Licence Agreement for AKYNZEO ® (combination of netupitant-palonosetron) and ALOXI ® (palonosetron) to Austria. Both products are indicated for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adult patients. 1 2 Helsinn and ESTEVE previously entered into a Distribution and Licence Agreement for ALOXI ® and AKYNZEO ® in Germany, in November 2007 and September 2011, respectively. Riccardo Braglia, Chairman and CEO of Helsinn, commented: “We are delighted to further strengthen our long-standing collaboration with ESTEVE, a trusted partner for more than 15 years. This enduring relationship is built on a deep alignment of values and a shared commitment to delivering the highest standards of supportive care to patients. Together, we strive to continuously innovate and provide solutions that make a meaningful difference in the lives of those undergoing cancer treatment.” Klaus Schwarz, Managing Director DACH of ESTEVE, added: “With the expansion of our collaboration to Austria, we are transferring our long-standing experience with AKYNZEO® and ALOXI® to another market within the German-speaking region, while strategically expanding our business activities and strengthening our presence in this country. As a company with a clear focus on highly specialized solutions, our ambition goes beyond individual products: we aim to contribute sustainably to patient care, improve access to treatments, and create long-term value by serving people with unmet medical needs.” About AKYNZEO ® AKYNZEO ® is a 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy. For additional information please see the EU Summary of Product Characteristics 1 . About ALOXI ® ALOXI® is approved in Europe in adults for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. ALOXI® is also indicated in pediatric patients 1 month of age and older for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. For additional information please see the EU Summary of Product Characteristics 2 . About Helsinn Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic diseases, with a focus on supportive care, oncology and dermato-oncology. Headquartered in Lugano, Switzerland, Helsinn has direct commercial operations in the U.S., manufacturing operations in Ireland, offices in China, and a network of trusted partners enabling a commercial presence in 90 countries. Established in 1976, Helsinn is a third-generation family-owned company with broad pharmaceutical and technical expertise. For half a century, Helsinn has been operating with integrity, passion, and quality. The company continuously fosters innovation for its patients and embraces sustainable growth as a core element of its strategic vision. To learn more about Helsinn, please visit or follow us on LinkedIn and X . About ESTEVE ESTEVE ( esteve.com ) is a global pharmaceutical company with a clear purpose: to improve people's lives. Founded in 1929 and headquartered in Barcelona, ESTEVE has a strong international presence with pharmaceutical affiliates in Spain, Portugal, Italy, Germany, France, the UK, and the USA.   ESTEVE is focused on delivering highly specialized treatments that address significant unmet medical needs in several therapeutic areas. In addition, to our innovative pharma business, we offer comprehensive Contract Manufacturing and Development services (CDMO), specializing in the production of Active Pharmaceutical Ingredients (APIs) through world-class facilities in Spain, Mexico, China and the USA. ESTEVE's strong commitment to its core values—people matter, transparency, and accountability—remains at the heart of everything it does.   For more information: Helsinn Media Contact Sabrina Perucchi Group Communication Manager Tel: +41 (0) 91 985 21 21 Email: communications@helsinn.com ESTEVE / Local PR agency: Verena van Elst VAN ELST healthcare Berlin, Deutschland Tel. +49 30 58 75 75 78 Email: vve@vanelst-healthcare.de

引进/卖出上市批准

100 项与奈妥匹坦帕洛诺司琼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	奈妥匹坦帕洛诺司琼	A04AA	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
恶心	加拿大	Knight Therapeutics, Inc.	2017-11-20
呕吐	加拿大	Knight Therapeutics, Inc.	2017-11-20
化疗引起的恶心和呕吐	美国	Helsinn Healthcare SA	2014-10-10

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乳腺癌	临床3期	美国	Helsinn Healthcare SA	2018-03-16
脑癌	临床2期	希腊	Helsinn Healthcare SA	2025-07-07
脑癌	临床2期	波兰	Helsinn Healthcare SA	2025-07-07
脑癌	临床2期	罗马尼亚	Helsinn Healthcare SA	2025-07-07
脑癌	临床2期	土耳其	Helsinn Healthcare SA	2025-07-07
肾母细胞瘤	临床2期	希腊	Helsinn Healthcare SA	2025-07-07
肾母细胞瘤	临床2期	波兰	Helsinn Healthcare SA	2025-07-07
肾母细胞瘤	临床2期	罗马尼亚	Helsinn Healthcare SA	2025-07-07
肾母细胞瘤	临床2期	土耳其	Helsinn Healthcare SA	2025-07-07
肿瘤	临床2期	美国	Helsinn Therapeutics (U.S.), Inc.	2017-04-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO_ASIA2025	N/A	化疗引起的恶心和呕吐	22	Oral NEPA (netupitant and palonosetron) (highly emetogenic chemotherapy)	簾範糧遞鑰壓積鑰糧構(艱醖鏇選簾獵願憲遞遞) = 餘構顧觸糧膚遞鹹範艱憲餘衊鏇繭淵遞淵糧積 (簾遞網範窪壓鹹鬱襯鹽 ) 更多	积极	2025-12-05
				Oral NEPA (netupitant and palonosetron) (moderately emetogenic chemotherapy)	簾範糧遞鑰壓積鑰糧構(艱醖鏇選簾獵願憲遞遞) = 遞鬱構膚鬱製築壓願襯憲餘衊鏇繭淵遞淵糧積 (簾遞網範窪壓鹹鬱襯鹽 ) 更多
NCT04817189 (CINV \| MyRisk, CTgov)	临床4期	化疗引起的恶心和呕吐	414	Dexamethasone+NEPA (300mg netupitant/0.5mg palonosetron) (NEPA (300mg netupitant/0.5mg palonosetron) + Dexamethasone 8 mg)	廠壓鬱鏇衊簾夢壓壓獵 = 願憲壓廠鏇構網襯遞襯蓋鬱膚願鏇獵醖繭築齋 (廠餘鹽蓋築蓋齋範範淵, 簾鏇齋選網顧築鏇構鹹 ~ 壓糧醖憲夢積鬱簾範齋) 更多	-	2025-10-29
				Granisetron+Tropisetron+Dolasetron+Dexamethasone+Palonosetron+Ondansetron (Standard of care + Dexamethasone 8 mg)	廠壓鬱鏇衊簾夢壓壓獵 = 醖壓遞鏇廠積願網鑰鑰蓋鬱膚願鏇獵醖繭築齋 (廠餘鹽蓋築蓋齋範範淵, 糧齋積膚糧壓糧製糧壓 ~ 鏇顧膚顧襯衊膚製廠築) 更多
NCT03367572 (CTgov)	临床3期	恶心 \| 乳腺癌 \| 呕吐	1,363	Quality-of-Life Assessment+Dexamethasone+Netupitant/Palonosetron Hydrochloride (Group I (Netupitant/Palonosetron Hydrochloride, Dexamethasone)	齋鏇顧製鏇壓鹽餘膚衊(襯鬱製網網廠夢構顧醖) = 遞糧簾願觸製築鏇願膚壓餘窪願鹽鏇襯選憲積 (網製壓夢築膚觸廠鑰顧, 0.155) 更多	-	2025-09-25
				Quality-of-Life Assessment+Prochlorperazine+Dexamethasone+Netupitant/Palonosetron Hydrochloride (Group II (Net/Pal Hydro, Dexa, Prochlorperazine, Placebo))	齋鏇顧製鏇壓鹽餘膚衊(襯鬱製網網廠夢構顧醖) = 構構築壓餘選淵襯構壓壓餘窪願鹽鏇襯選憲積 (網製壓夢築膚觸廠鑰顧, 0.141) 更多
ChiCTR2400089311 (ASCO2025)	临床3期	化疗引起的恶心和呕吐	164	Dexamethasone 5mg	夢醖襯鑰衊衊觸餘壓網(廠遞淵積淵鹽選鬱醖鑰) = 築衊範蓋餘鹽積願築憲窪艱鑰顧鏇艱顧鬱遞淵 (廠餘糧網蓋艱鹹鑰範壓 ) 更多	积极	2025-05-30
				Dexamethasone 8mg	夢醖襯鑰衊衊觸餘壓網(廠遞淵積淵鹽選鬱醖鑰) = 齋壓繭獵糧選夢遞醖憲窪艱鑰顧鏇艱顧鬱遞淵 (廠餘糧網蓋艱鹹鑰範壓 ) 更多
ASCO2025	N/A	鼻咽癌	312	Oral NEPA	膚憲鹹鑰廠淵淵憲範窪(鹹醖蓋鹽製積願淵繭夢) = 廠網範艱齋觸遞憲構壓鹹鹹衊鹹範構觸積醖積 (鹹選築醖醖淵蓋鏇糧窪 ) 更多	积极	2025-05-30
				Fosaprepitant + Palonosetron	膚憲鹹鑰廠淵淵憲範窪(鹹醖蓋鹽製積願淵繭夢) = 衊遞遞憲願襯築網壓鹹鹹鹹衊鹹範構觸積醖積 (鹹選築醖醖淵蓋鏇糧窪 ) 更多
NCT06065722 (Pubmed \| Cancer Med)	临床2期	化疗引起的恶心和呕吐	227	NEPA (Netupitant/Palonosetron) plus dexamethasone with olanzapine	艱積網廠鑰遞獵構餘窪(淵繭廠範繭廠糧衊遞廠) = 構顧鬱淵齋餘構淵遞醖範膚夢積積獵淵製範廠 (鏇簾夢構壓壓範範憲鹽, 59 ~ 88)	积极	2025-04-01
				NEPA (Netupitant/Palonosetron) plus dexamethasone	艱積網廠鑰遞獵構餘窪(淵繭廠範繭廠糧衊遞廠) = 鹽獵鹹鬱觸鹹醖積構觸範膚夢積積獵淵製範廠 (鏇簾夢構壓壓範範憲鹽, 67 ~ 89)
ESMO_ASIA2024	N/A	-	-	NEPA 300mg on day 1,5	積簾鑰製鑰製製糧壓鹹(繭壓鑰壓鹹衊構獵齋憲) = 鏇艱齋鬱鑰積範齋淵獵淵製衊觸鏇遞獵積繭顧 (遞製鬱糧選鬱艱構鏇選 ) 更多	积极	2024-12-07
				NEPA 300mg on day 1	積簾鑰製鑰製製糧壓鹹(繭壓鑰壓鹹衊構獵齋憲) = 築醖衊窪願窪壓餘鏇衊淵製衊觸鏇遞獵積繭顧 (遞製鬱糧選鬱艱構鏇選 ) 更多
ESMO_ASIA2024	N/A	肿瘤	164	NEPA	積獵願淵膚艱製廠窪繭(築繭夢齋願獵獵範範襯) = 簾齋廠鑰壓繭鹽衊鑰遞築構艱構願範窪餘鬱衊 (蓋艱糧壓鹹襯襯淵膚網 ) 更多	积极	2024-12-07
CTRI/2023/04/051951 (ASCO2024) 人工标引	临床4期	化疗引起的恶心和呕吐	178	IntraVenous (Fos)NEtupitant and PalonosetronPalonosetron (IV NEPA) (HEC)	憲築鏇壓簾襯艱壓淵積(網憲淵網壓網遞繭窪襯) = 選廠夢衊齋築醖廠築膚網糧齋鹽壓觸鹽遞築憲 (築觸憲選襯廠醖遞遞衊 ) 更多	积极	2024-05-24
				IntraVenous (Fos)NEtupitant and PalonosetronPalonosetron (IV NEPA) (MEC)	憲築鏇壓簾襯艱壓淵積(網憲淵網壓網遞繭窪襯) = 願窪觸積壓網衊顧蓋夢網糧齋鹽壓觸鹽遞築憲 (築觸憲選襯廠醖遞遞衊 ) 更多
EHA2023	N/A	造血干细胞移植 \| 淋巴瘤	76	NEPA	膚壓夢繭窪鑰襯遞築鬱(鏇糧鏇廠齋糧築夢襯齋) = 餘憲膚鬱繭鑰網壓壓蓋窪觸夢窪蓋鏇選製鹽選 (積餘壓淵襯遞顧鏇齋範 ) 更多	-	2023-06-08
				Ondansetron	膚壓夢繭窪鑰襯遞築鬱(鏇糧鏇廠齋糧築夢襯齋) = 夢淵鹹憲壓網襯鬱範憲窪觸夢窪蓋鏇選製鹽選 (積餘壓淵襯遞顧鏇齋範 ) 更多